For the quarter ending 2026-03-31, GALT has $15,759K in assets. $145,996K in debts. $14,111K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 14,111 | 17,720 | 11,525 | 13,771 |
| Prepaid expenses and other current assets | 1,580 | 1,716 | 1,204 | 1,656 |
| Total current assets | 15,691 | 19,436 | 12,729 | 15,427 |
| Other | 68 | 96 | 136 | 175 |
| Total assets | 15,759 | 19,532 | 12,865 | 15,602 |
| Current portion of convertible notes payable and accrued interest, net of debt discounts related party (note 5) | - | 0 | 32,521 | 0 |
| Current portion of derivative liabilities (note 6) | - | 0 | 3,742 | 0 |
| Accounts payable | 3,121 | 3,245 | 5,390 | 5,865 |
| Accrued expenses | 4,186 | 4,722 | 5,038 | 4,846 |
| Borrowing and accrued interest under convertible lines of credit, net of debt discount related party (note 9) | - | - | 89,754 | - |
| Accrued dividends payable | 0 | 63 | 0 | 63 |
| Total current liabilities | 7,307 | 8,030 | 136,445 | 10,774 |
| Convertible notes payable and accrued interest, net of debt discounts related party (note 5) | 32,878 | 32,702 | 0 | 32,308 |
| Derivative liabilities (note 6) | 2,979 | 3,962 | 0 | 1,537 |
| Borrowing and accrued interest under convertible line of credit, net of debt discount related party (note 10) | 102,832 | 101,033 | 0 | 88,150 |
| Total liabilities | 145,996 | 145,727 | 136,445 | 132,769 |
| Series c 6 super dividend redeemable convertible preferred stock 1,000 shares authorized, 176 issued and outstanding at march 31, 2026 and december 31, 2025, redemption value 7,966,000, liquidation value 1,760,000 at march 31, 2026 | 1,723 | 1,723 | 1,723 | 1,723 |
| Series a 12 convertible preferred stock 1,742,500 shares authorized, 1,185,000 and 1,210,000 issued and outstanding at march 31, 2026 and december 31, 2025, respectively, liquidation value 1,210,000 at march 31, 2026 | 480 | 490 | 490 | 490 |
| Common stock, 0.001 par value 150,000,000 shares authorized at march 31, 2026 and december 31, 2025, 65,856,898 and 65,201,995 issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 65 | 65 | 64 | 63 |
| Additional paid-in capital | 305,108 | 304,073 | 301,127 | 299,318 |
| Accumulated deficit | -437,613 | -432,546 | -426,984 | -418,761 |
| Total stockholders deficit | -131,960 | -127,918 | -125,303 | -118,890 |
| Total liabilities, redeemable convertible preferred stock and stockholders deficit | 15,759 | 19,532 | 12,865 | 15,602 |
GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC (GALT)